Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Nov 5;20:142. doi: 10.1186/s12943-021-01443-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — ciRS-7 enhances RCC tumor growth and metastasis in vivo and PBAE/si-ciRS-7 nanocomplexes inhibits RCC growth and metastasis in vivo. A. The sizes with different weight ratios of PBAE to siPlk1. The weight ratios of PBAE to si-ciRS-7 were ranged from 1 to 120. B. The loading efficiency of PBAE. C. TEM images of PBAE/si-ciRS-7 nanocomplexes (PBAE/si-ciRS-7 = 80/1). D. size distribution of PBAE/si-ciRS-7 nanocomplexes (PBAE/si-ciRS-7 = 80/1). E. Graphic illustration of the in vivo mice model study. F-H. 786-O cells stably transfected with OE-ciRS-7, control, or sh-ciRS-7 were injected subcutaneously into the mice. Tumor volume (G) and weight (H) increased in the OE-ciRS-7 group, while both tumor volume and weight decreased in the sh-ciRS-7 group. I. IHC assay demonstrated the level of TAGLN and Ki67 in pairs of tumours. J. After tail vein injection of treated cells, imaging, gross lung tissue lesions and HE staining were observed. K. The flow diagram showed the scheme of intratumorally/intravenously with saline, si-ciRS-7 or PBAE/si-ciRS-7 into mice. L-N. Weight volume and weight change after 3 weeks of treatment with saline, si-ciRS-7 or PBAE/si-ciRS-7 for xenograft tumors or lung metastasis models. O. IHC assay demonstrated the level of TAGLN and Ki67 in pairs of tumours. P. IVIS imaging of mice treated with saline, si-ciRS-7 or PBAE/si-ciRS-7 for subcapsular orthotopic implantation of the right kidney. Q. After tail vein injection of treated cells, imaging, gross lung tissue lesions and HE staining were observed. R. The hypothetical model depicts the roles of ciRS-7 in the promotion of RCC. (*p < 0.05, **p < 0.01, ***p < 0.001)